NASDAQ:EPRX Eupraxia Pharmaceuticals Q3 2026 Earnings Date & Estimates $7.46 -0.11 (-1.45%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$7.64 +0.18 (+2.41%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Eupraxia Pharmaceuticals is expected to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeBefore Market OpensConference Call DateNovember 5, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Eupraxia Pharmaceuticals in Q3 2026Eupraxia Pharmaceuticals is expected to post earnings of -$0.26 per share. In the same quarter a year earlier Eupraxia Pharmaceuticals reported -$0.19 per share. Eupraxia Pharmaceuticals last reported on August 11, 2026, posting -$0.23 per share and beating the -$0.25 consensus estimate. Eupraxia Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.26Prior-Year EPS-$0.19Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.23 (Beat by +$0.02)EPS Beat Rate2 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Eupraxia Pharmaceuticals Q3 2026 Earnings FAQ When does Eupraxia Pharmaceuticals report Q3 2026 earnings? Eupraxia Pharmaceuticals (NASDAQ:EPRX) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Eupraxia Pharmaceuticals' Q3 2026 earnings call? Eupraxia Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Eupraxia Pharmaceuticals? Analysts expect Eupraxia Pharmaceuticals to post earnings of -$0.26 per share for Q3 2026. Eupraxia Pharmaceuticals Earnings HeadlinesEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesOctober 9 at 8:10 AM | financialpost.comFEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesOctober 9 at 8:00 AM | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 10 at 1:00 AM | Stansberry Research (Ad)Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 10.2% - Should You Sell?October 3, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX)October 3, 2026 | americanbankingnews.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Jumps 6.5% - What's Next?October 2, 2026 | americanbankingnews.comSee More Eupraxia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email. Email Address About Eupraxia PharmaceuticalsEupraxia Pharmaceuticals (NASDAQ:EPRX) (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions. Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee. The company’s approach is intended to provide sustained drug delivery within the affected joint and is based on its proprietary DiffuSphere technology. The company has also developed EP-7041, an investigational small-molecule inhibitor of factor XIa being evaluated for its potential use in preventing and treating blood clots. Eupraxia does not currently have marketed products and remains focused on research, clinical development and potential commercialization through regulatory approval and strategic partnerships.View Eupraxia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
